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1. INTRODUCTION 
Tuberculosis is an infectious disease usually caused by the bacteria 
Mycobacterium tuberculosis. Tuberculosis may infect any part of the body, but most 
commonly occur in the lungs (known as pulmonary tuberculosis). Extrapulmonary TB 
occurs when tuberculosis develops outside of the lungs. Extrapulmonary TB may co exist 
with pulmonary TB. The classic symptoms of active TB are chronic cough with blood- 
tinged sputum, fever, night sweats and weight loss. Tuberculosis is spread through the air 
when people who have active TB in their lungs cough, spit, speak or sneeze.(1-2) Active 
infection occurs more often in people with HIV/AIDS and in those who smoke. 
One third of the world  population is thought to be infected with TB .(1) New 
infection occur in about 1% of the population each year.(3) In  2014 , there  where  9.6 
million case of active TB which resulted in 1.5 million deaths .More than 95% of deaths 
occurred in developing countries (1). About 80% of the people in many Asian and African 
countries test positive while 5-10 % of people in the United Status population tests 
positive by  the tuberculin test .Tuberculosis has been present in humans since ancient 
times .(4) 
GENERAL SIGNS AND SYMPTOMS 
General signs and symptoms include fever, chills, night sweats, loss of appetite, 
weight loss, and fatigue. Significant nail clubbing may also occur. (5) 
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Figure. 1 (6) 
 
BACKROUND 
Tuberculosis or TB is the most common infectious disease. In the past 
Tuberculosis also called as phthisis or phthisis pulmonalis. TB is second only to 
HIV/AIDS as the greatest killer worldwide due to the single infectious agent.(7) 
In addition, the prevalence of drug-resistant TB is also increasing worldwide. Co-
infection with HIV has been an important factor in the emergence in the spread of 
resistance.(8) New TB treatments are being developed and new vaccines are currently 
under investigation(9). TB is a major global health threat, and we must improve the 
existing treatment regimen to control the spread of TB. 
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HISTORY 
M. Tuberculosis, then known as the "Tubercle Bacillus", was first described on 24 
March 1882  by  Robert  Koch, WHO subsequently received  the Nobel Prize in 
physiology or medicine for this discovery in 1905; The Bacterium is also known" Koch's 
Bacillus".(10)  Tuberculosis has existed throughout history, but the name has changed 
frequently over time.  In 1720, though, the History of Tuberculosis started to take shape 
into what is known of it today, as the physician Benjamin Marten described in his A 
Theory of Consumption, Tuberculosis may be caused by small living creatures 
transmitted through the air to other patients. (11) 
MYCOBACTERIA 
The main cause of TB is Mycobacterium tuberculosis which is a rod shaped, 
small, aerobic, non motile bacillus. The high lipid content of this pathogen accounts for 
many of its unique clinical characteristics. It divides every 16 to 20 hours .Which is an 
extremely slow rate compared with other bacteria. Mycobacteria have an outer membrane 
lipid bilayer. If a gram stain is performed, MTB either stains very weekly gram – positive 
or does not retain dye as a result of the high lipid and mycolic acid content of its cell wall 
(12). In nature the bacterium can grow only within the cells of a host organism, but 
M.tuberculosis can be cultured in the laboratory. Since MTB retains certain stains even 
after being treated with acidic solution, it is classified as an acid-fast bacillus. (13) 
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`Figure. 2 (14) 
 
SCIENTIFIC CLASSIFICATION 
Kingdom           :  Bacteria 
Phylum             :  Actinobacteria 
Class                 :  Actinobacteria 
Class                 :  Actinomycetalus 
Sub Order         :  Corynebacterineae 
Family              :  Mycobacteriaceae 
Genus               :  Mycobacterium 
Species             :          Mycobacterium tuberculosis (15) 
CELL WALL 
The well-developed cell wall contains a considerable amount of a fatty acids, 
mycolicacid  which is  covalently  attached to the underlying  peptidoglycon-bound 
polysaccharide  arabinogalactan , providing an extra ordinary lipid barrier .This barrier is 
responsible for many of the medically challenging physiological characteristics of  
tuberculosis. The composition and quality of the cell wall components affect the 
bacteria’s virulence and growth rate. 
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The peptidoglycan polymer confers cell wall rigidity and just external to the 
bacterial cell membrane another contributer to the permeability barrier of mycobacteria. 
The peptidoglycan   polymer confers cell wall rigidity. 
Another important component of the cell wall is lipoarabinomannan, a 
carbohydrade structural antigen on the organism that is immunogenic and facilitates the 
survival of mycobacteria within macrophages. The cell wall is key to the survival of 
mycobacteria and a more complete understanding of the biosynthetic pathways and gene 
functions and the development of antibiotics to prevent formation of the cell wall are 
areas of great interest.(16) 
Figure. 3(17) 
 
DRUG RESISTANT TB 
Drug-resistant TB disease can develop in two different ways, called primary and 
secondary resistance. Primary resistance occurs in persons who are initially exposed to 
and infected with resistant organisms .Secondary resistance, or acquired resistance, 
develops during TB therapy, either because the patient was treated with an inadequate 
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regimen or did not take the prescribed regimen appropriately, or because of other 
conditions such as drug malabsorption or drug-drug interactions that led to low serum 
levels. 
MDR TB is caused by organisms resistant to both isoniazid and rifampicin, 
which are the two most effective anti-TB drugs .These drugs are considered first-line 
drugs and are used to treat most persons with TB disease. 
XDR TB is  relatively rare type of drug- resistant TB .XDR TB is resistant to 
isoniazid  and rifampicin  ,plus any  fluoroquinolone  and at least one of three injectable  
second-line drugs  (i.e., amikacin,  kanamycin, orcapreomycin).Because XDR TB disease 
is resistant to first-line and second-line drugs ,patients are left with treatment options that 
are more toxic ,more  expensive, and much less effective. 
THE NEED FOR NOVEL TUBERCULOSIS DRUGS 
1. To improve current treatment by shortening the total duration of treatment 
2. To improve the treatment of MDR-TB[18] 
3. To provide for more effective treatment of latent tuberculosis infection (16) 
4. New drugs to improve current drugs that facilitate compliance by providing for 
less intensive supervision are also of great interest 
5. Discovery of a compound that would reduce both the total length of treatment and 
the frequency of drug administration 
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6. MDR TB must be treated with a combination of “second line” drugs which are not 
only more expensive but also much more toxic and less effective than the drugs used 
in standard therapy.(19) 
GENOME 
The Mycobacterium Tuberculosis genome encodes about 190 transcriptional 
regulators, including is sigma factors, two-component system and more than 140 
transcription regulators. Several regulators have been found to respond to environmental 
distress, such as extreme cold or heat, iron starvation, and oxidative stress. To survive in 
these harsh conditions for a prolonged period in the host, Mycobacterium tuberculosis 
had learned to adapt to the environment by allowing an inhibiting transcription according 
to it’s surrounding. (20) 
GENOME STRUCTURE 
Mycobacterium tuberculosis has circular chromosomes of about 4,200,000 
nucleotides long .The genome of M.tuberculosis was studied generally using the strain 
M.tuberculosis H37Rv. The genome contains about 4000 genes. Genes that code for lipid 
metabolism are very important for the bacterial genome, and 8% of the genome is 
involved in this activity.(21) Plasmid in M.tuberculosis is important in transferring 
virulence because genes on the plasmids are more easily transferred than genes located 
on the chromosomes. One such 18kb plasmid in the M.tuberculosis H37Rv strain was 
proven to conduct gene transfers. (22) 
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Figure. 4 (22)   The chromosome of M.Tuberculosis H37Rv and the gene synthesise 
mycolic acids. 
 
 
CHOLESTROL METABOLISM 
Cholesterol metabolism has been studied extensively because of its possible 
therapeutic application in TB infections. It has been shown numerous times that TB 
requires cholesterol for virulence in vivo, because Mycobacterium Tuberculosis (Mtb); 
the causative agent, utilizes cholesterol as a source of carbon, energy, and steroid-derived 
metabolites throughout the course of infection. (23) 
ROLE OF CHOLESTROL IN TB INFECTION 
Tuberculosis infection has unique virulence factors compared to most pathogens. 
The infect host cell and persist inside phagosome, where there are limited nutrients. 
Tuberculosis has unique ability to utilize cholesterol, which is a common component of 
human cell membrane, plays a role in its   persistence, because the cholesterol catabolism 
pathway requires a large number of oxygen, that TB infect the lungs where oxygen 
concentrations are highest.(24) 
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PATHOPHYSIOLOGY OF TUBERCULOSIS 
Mycobacterium tuberculosis requires high levels of oxygen to grow. Primarily a 
pathogen of the mammalian respiratory system, it infect the lungs .The most frequently 
used diagnostic methods for TB are the tuberculin test, acid- fast stain, and chest 
radiographs.(25) 
M.tuberculosis is divides every 15-20 hours, which is extremely slow, compared 
to other bacteria. It is a small bacillus that can withstand weak disinfectants and can 
survive in a dry state for weeks. Its unusual cell wall, rich in lipids (e.g. mycolic 
acids).(26) Humans are the only known reservoirs of Mycobacterium tuberculosis. When in 
the lungs, mycobacterium tuberculosis is taken up by alveolar macrophages, but they are 
unable to digest  and eradicate the bacterium. It cell wall prevents the fusion of the 
phagosome with theylosome, which contains host of anti- mycobacterial factors. (27) 
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Figure. 5 (28) Pathophysiology of tuberculosis 
 
 
(A)   inhalation of bacilli,  (B) containment in the granuloma ,( C) Breakdown of the 
granuloma in less immunocompetent individuals . 
Need for new anti-TB drugs 
 The recent rise in TB cases and especially the increase of drug resistant 
mycobacteria indicate an urgent need to develop new anti-TB drugs. 
 The long duration of TB therapy is a consequence of persistent mycobacterium 
tuberculosis, not effectively killed by current anti-TB agents. (29) 
  Recent advances in the knowledge of the biology of the organism and the 
availability of the genome sequence give an opportunity to explore a wide range 
of novel targets for drug design. 
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 It is expected that the application of functional genomic tools, such as structure 
based drug design and combinatorial chemistry will lead to the development of 
new drugs that are active against drug resistant TB. (30) 
  There is a need to design new drugs that are more active against slowly growing 
and non growing persistent bacilli to meet the population at risk of developing 
active disease through reactivation. 
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ENZYME PROFILE 
Mycolic acids, a homologous series of C60-C90 long-chain alpha-alkyl- and beta 
hydroxyl fatty acids, represent essential components of the mycobacterial cell wall. They 
are important for mycobacterial growth, survival, and pathogenicity. They are found as 
esters of anarabinogalactan as well as free lipids in the form trialosedimycolate 
(TDM).Arabinogalactanmycolate is covalently linked to the cell wall peptidoglycan via a 
phosphodiester bond located on the inner leaflet of the outer membrane. Both 
arabinogalactan and TDM provide a protective thick cell wall and protect the tubercle 
bacillus from antibiotics and host‘s immune system.TDM also inhibits phagolysosome 
fusion and is often considered to be an indicator of virulent strains. 
Figure. 6(31) 
 
 
 
Three distinct structural classes of mycolic acids namely alpha-(more than 
70percent), methoxy-and keto-mycolic acids (10-15%) are found in this bacillus. 
Methoxy-mycolic acids, which contain several methoxy groups, comprise between 10 to 
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15% of the mycolic acids in the organism. The alpha-mycolic acid is a cis, cis-
dicyclopropyl fatty acid. Both methoxy-and keto- mycolic acids have either cis- or trans- 
cyclopropane rings. Cyclopropane rings in mycolic acids protect the bacillus from 
oxidative stress. 
Several front-line drugs used for treating tuberculosis inhibit mycolic acid 
synthesis. Understanding the pathway of mycolate biosynthesis and the underlying 
molecular mechanisms of the disease tuberculosis a well as the identification of new 
antituberculosis drug targets is important. InhA(ECn1.3.1.9,enoyl-[acyl-carrier-
protein]reductase), involved in mycolic acid synthesis ,is a target of front-line anti-
tubercular drugs, such as isoniazid and ethionamide. Enzymes needed for biosynthesis of 
mycolic acids, such as methoxy mycolic acid synthase2, cyclopropane mycolic acid 
synthase 2, methyl transferase (PcaA),beta-ketoacyl-acyl carrier protein synthase (KasAB 
and FabH),acyl-AMP ligase (Fad32) and polyketide synthase(Psk13) are promising drug 
targets for new anti-TB agents.(31) 
The presence of mycolic acids gives M.tuberculosis many characteristics that defy 
medical treatment.Theylend the organism increased resistance to chemical damage and 
dehydration, and prevent the effective activity of hydrophobic antibiotics .In addition, the 
mycolic acids allow the bacterium to grow readily inside macrophages, effectively hiding 
it from the host's immune system. Mycolate bio- synthesis is crucial for survival and 
pathogenesis of M. Tuberculosis.(32-33) 
Five distinct stages are involved in biosynthesis of mycolic acid these were 
summarized as follows 
  Synthesis of the C26 saturated straight chain fatty acids by the enzyme fatty  
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                acid    synthase -I (FAS-I) to provide the α-alkyl branch of the mycolic acids. 
  Synthesis of the C56 fatty acids by FAS-II providing the meromycolate   
          backbone. 
  Introduction of functional groups to the meromycolate chain by numerous     
     Cyclopropane synthases. 
 Condensation reaction catalysed by the polyketide synthase Pks13 between the              
 α-branch and the meromycolate chain before a final reduction by the enzyme     
 Corynebacterineae mycolate reductase A (CmrA) to generate the mycolic acid;  
 and Transfer of mycolic acids to arabinogalactan and other acceptors such as  
 trihalose via the antigen 85 complex. 
 The fatty acid synthase-I and fatty acid synthase-II pathways producing    
       mycolic acids are linked by beta-ketoacyl-(acyl-carrier-protein) synthase III  
       enzyme, often designated as mtFabH. Novel inhibitors of  this enzyme could  
       potentially be used as therapeutic agents.(34) 
 MmA2 is required for introduction of the distal cyclopropane ring in the  
       formation of meroacids. Analysis of a mmA2 deletion mutant of Tuberculosis  
       revealed that mycolic acid lacks a distal cyclopropane group and instead contains  
       a cis unsaturation. Thus, mmA2 is required for the distal cyclopropane  
       modification of mycolic acid. (35) 
 
 
 
 
Introduction 
 
Department of Pharmaceutical chemistry  Page 15 
 
Figure .7 (33) Methoxy Mycolic Acid Synthase 2 
 
 
 
 ENZYME NAME                            :  Methoxy mycolic acidsynthase2 
 GENE NAME                                  :  mmA2, mmaA2, RV0644C 
 CLASSIFICATION                          : Transferase 
 STRUCTURE WEIGHT                  : 33493.47 
 POLYMER                                         :    1 
 TYPE                                                  :      Protein 
 CHAINS                                             :      A 
 ORGA\NISM                                     :   Mycobacterium tuberculosis 
 PROTEOME                                     :  Chromosome 
 FUNCTIONAL CATEGORY         :           Lipid metabolism  (35) 
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BASIC NUCLEUS PROFILE 
THIOPHENE 
Tiophene, a heterocyclic nucleus has attracted a wide attention of the chemist in 
search for the new therapeutic molecules. Thiophene, also called as thiofuran, is a 
heterocyclic compound with the formula C4H4S. It consists of a flat five membered ring, 
it is aromatic as indicated by its extensive substitution reactions. Related to thiophene are 
benzothiophene, and dibenzothiophene, containing the thiophene ring fused with one and 
two benzene rings, respectively (36). 
Figure. 8 
 
IUPAC NAME 
Thiophene 
Other names 
Thiofuran 
Thiacyclopentadiene 
Thiole 
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PROPERTIES 
Chemical formula       :      C4H4S 
Molar mass                 :       84.14 g/mol 
Appearance                :       colorless liquid 
Density                       :      1.051g/ml 
Melting point             :     - 38c 
Boiling point              :     84c 
Refractive index        :    1.5287(36) 
USES 
Thiophenes are important heterocyclic compounds that are widely used as 
building blocks in many agrochemicals and pharmaceuticals.The benzene ring of a 
biologically active compound may often be replaced by a thiophene without loss of 
activity. This is seen in examples such as the NSAID Iornoxicam, the thiphene analog of 
piroxicam. (37) 
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2. REVIEW OF LITERATURE 
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in drug discovery”. 
17. Lipinski C A et.al (2004) (62) “Lead and Drug-like compounds: the rule-of-five 
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Literature review for spectroscopy 
19. Gurdeep R Chatwal et.al (2005) (64) wrote a book on, Instrumental methods of 
chemical analysis. 
20. P S Kalsi (65) Text book on Spectroscopy of organic compounds. 
21. D Kealey et al., (66) Text book on Instant notes Analytical Chemistry. 
22. Y. R. Sharma (55)Tezole chalconext book on Elemental Organic Spectroscopy. 
Literature review on chalcones 
23. Bijo Mathew A J et.al.,(2012)(53) The benzimidazole nucleus exhibits wide range of 
biological activities. The aim of our research was incorporate a barbitone pharmacophore 
to the benzimidazole chalcones by means of a C=C bond and improve its bioactive 
nature.The final compound were screened for antimicrobial studies.All the compounds 
showed a good activity towards Gram positive bacteria and less activity towards Gram 
negative bacteria.The present study described the synthesis of novel derivatives of 5-
[(2E)-1-(1H-benzimidazole-2-yl)-3-substituted phenylprop-2-en-1-ylidene] pyrimidine-
2,4,6(1H,3H,5H)-trione by bothconventional and microwave assisted.Here the 
establishment of  physic chemical describer is a good tool for the prediction of 
antimicrobial activities. 
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24. Rajarkur R. B et.al.,(2012) reported that study various chalcones were synthesized by 
the base catalyzed reaction between substituted aromatic ketones and substituted aromatic 
aldehydes. These chalcones were then subjected to the reaction with hydroxyl amine 
hydrochloride, guanidine hydrochloride and isoniazid to give 3,5- disubstituted 
isoxazoles, 4,6-disubstituted pyrimidine-2-amines and 3,5-disubstituted pyrazole 
derivatives respectively.  These compounds were evaluated for their good antimicrobial, 
antifungal and antitubercular activity. 
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25. Naik A V et.al .,(2005) reported that, The chalcones are associated with different 
biological activities like insecticidal, anticancer, anti-inflammatory, bactericidal, 
fungicidal, antiviral, antitumor, antimalarial and antiulcer. Literature shows that 
lieochalcone and oxygenated chalcone has strong antileishmanial activity. It is reported 
that chalcones exhibited potent activity against human malarial parasite. Many workers 
have reported the different pharmaceutical activities of chalcones and its derivatives. 
 
Br
HO
C2H5
O
R
 
 
26. Rane et.al.,(2010) have reported synthesis of a acetylenic chalcones. The new 
acetylenic chalcones were evaluated for antimalarial and antitubercular activity. The 
antimalarial data for this series suggests that growth inhibition of the W2 strain of 
Plasmodium falciparum can be impacted by the introduction of a methoxy group ortho to 
the acetylenic group. Most of the compounds were active against Mycobacterium 
tuberculosis H37Rv. 
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27.   Babasaheb et.al.,(2010)11 have reported synthesis and biological evaluation of β-
chloro vinyl chalcones. All synthesized compounds were evaluated for their anti-
inflammatory activity and antimicrobial activity. Most of compounds showed very good 
antibacterial and antifungal activity. 
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28. Jen-Hao et.al.,(2008)14 have reported synthesis of 2,5-dialkoxylchalcones. The new 
chalcones were prepared by Claisen–Schmidt condensation of appropriate acetophenones 
with suitable aromatic aldehyde. The novel 2,5-dialkoxylchalcones were evaluated for 
their cytotoxic, anti-inflammatory,  anti-oxidant ,anti tubercular activity. 
 
S
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Literature review on thiophene nucleus 
29.Thaker K M et.al.,(2007) reported that the synthesis of 4,thiazolidinone and 
2,azetidinones bearing benzo(b) thiopjhene nucleus as potential anti tubercular and 
antimicrobial agents .In this anti tubercular evaluation of compound wsa carried out at 
tuberculosis antimicrobial acquisition co ordination facility(TAACF) .M.tuberculosis 
H37Rv to determined the actual minimum inhibitory concentration (MIC) in the 
BACTEC 460 the antitubercular activity data have been compared with standard drug 
rifampin at 0.25 microgram per ml. Concentration and it showed 98%inhibition . 
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30.    Parvesh Singh P S et.al .,(1999)  Sulphur compounds are of great chemical and 
pharmaceutical significance and display diverse properties such as antifungal,
 
anti-
HIV,antipsoratic,and antimicrobial activities.
 
Some imidazo[2,1-b]-[1,3]thiazines and 
pyrimido[2,1-b]-[1,3]thiazines are well known anti-inflammatory agents.
 
Likewise, 
thiophene compounds are well known to exhibit various biological and medicinal 
activities such as BACE1 inhibitors, antitubercular, anti-depressant,
 
anti-inflammatory,
 
anti-HIV PR inhibitors,
 
and anti-breast cancer activities. 
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31. Ashish Das et.al., (2014) studied that A variety of biological and pharmacological 
importance of thiophene makes it an essential pharmacophore in the field of medicinal 
chemistry. Already marketed drugs like Clavix, Plavix which acts by irreversible 
inhibition of P2Y12 receptor, Tioconazole, a proven fungicidal agent which acts by 
inhibition of cell wall synthesis having thiophene core has been proven to be efficacious 
drugs in present respective disease scenario. Thus the synthesis and characterization of 
novel thiophene moieties with wider therapeutic consequences is a topic of interest for 
the medicinal chemist. This mini review enumerates the reported synthetic strategy to 
synthesize thiophene and its major therapeutic field as exploited in the literature. 
S OH
O
 
 
32. Raghav Mishr K K et.al.,(2011) studied that, Thiophene nucleus has been established 
as the potential entity in the largely growing chemical world of heterocyclic compounds 
possessing promising pharmacological characteristics. thiophenes significantly important 
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class of heterocyclic compounds and their applications in ever challenging chemotherapy 
of various ailments/ infections etc. 
S
R
OR
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33. Sahar M I et.al .,(2010) It has been reported in the literature that heterocyclic 
compounds such as thiophenes exhibited potent anti-inflammatory activity.  Likewise, 
thiazole, 1, 3, 4-thiadiazole, and their derivatives were found to possess anti tubercular 
and anti inflammatory activities. 
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3. AIM AND OBJECTIVE 
AIM 
The aim of this project is to discover molecules with potential anti -tubercular activity. 
OBJECTIVE 
Design compounds and docked against a specific crucial target, Methoxy Mycolic acid 
Synthase 2, which is involved in the cell wall synthesis. The synthesized compounds are 
expected to act on this enzyme. 
THE PLAN OF WORK 
 Design of methoxy mycolic acid synthase 2 inhibitors by docking studies. 
 Insilico Drug likeness prediction. 
 Insilico Toxicity Assessment. 
 Laboratory synthesis of the compounds with top Docking Scores. 
 Characterization of the synthesized compounds by 
 Infrared Spectroscopy. 
 H1 Nuclear Magnetic Resonance Spectroscopy. 
 C13 Nuclear Magnetic Resonance Spectroscopy. 
 Mass Spectroscopy. 
 In-vitro anti -tubercular activity of synthesized compounds (MABA). 
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The whole study was carried out according to this flow chart 
 
Identification of basic nucleus 
↓ 
Structural Modification of the basic Nucleus 
↓ 
Docking the molecule in the target protein 
↓ 
Optimization of the highly Interacting molecule 
↓ 
Top G score compounds selected 
↓ 
Synthesis 
↓ 
Characterization-Spectroscopy(IR,NMR,MASS) 
↓ 
Acute toxicity studies 
↓ 
               Invitroanti tubercular activity    
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4. MATERIALS AND METHODS 
DOCKING STUDIES 
Drug design 
Drug design is carried out using an automated docking program like GLIDE (grid based 
ligand docking with energetics) maestro 9.0 Schrodinger suites, Auto Dock or Argus Lab. It 
helps search molecules (ligands) having maximum favorable interactions with a receptor (target) 
usually a protein. Ligand is a single molecule whereas receptor may include proteins, metals and 
cofactors. It runs on rigid and flexible docking modes. The later which one generates 
conformations automatically for the input of each ligand and gives out the best fit pose of the 
molecule been docked on the receptor. (38) 
Types 
There are two major types of drug design. The first is referred to as ligand based drug 
design and the second, structure based drug design. 
1. Ligand based 
Ligand based drug design (or indirect drug design) relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be used to 
derive a pharmacophore model that defines the minimum necessary structural characteristics. A 
molecule must possess in order to bind to the target. (39)  In other words, a model of the biological 
target may be built based on the knowledge of what binds to it, and this model in turn may be 
used to design new molecular entities that interact with the target. Alternatively a quantitative 
structure activity relationship (QSAR), in which a correlation between calculated properties of 
molecules and their experimentally determined biological activity, may be derived. These QSAR 
relationships in turn may be used to predict the activity of new analogs. 
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Figure. 9 
 
 
2. Structure based 
Structure based drug design (or direct drug design) relies on knowledge of the three 
dimensional structure of the biological target obtained through methods such as x-ray 
Crystallography or NMR spectroscopy. (40) If an experimental structure of a target is not 
available, it may be possible to create a homology model of the target based on the experimental 
structure of a related protein. Using the structure of the biological target, Candidate drugs that 
are predicted to bind with high affinity and selectivity to the target may be designed using 
interactive graphics and the intuition of a medicinal chemist. Alternatively various automated 
computational procedures may be used to suggest new drug candidates. 
The 3D structures of bio molecular targets are obtained from X-ray Crystallography and 
NMR. In parallel, information about the structural dynamics and electronic properties about 
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ligands are obtained from calculations. This has encouraged the rapid development of the 
structure based drug design. (s 
 
Figure. 10 (42) 
 
COMPUTER-AIDED DRUG DESIGN 
Computer-aided drug design uses computational chemistry to discover, enhance, or study 
drugs and related biologically active molecules. Molecular mechanics or molecular dynamics are 
most often used to predict the conformation of the small molecule and to model conformational 
changes in the biological target that may occur when the small molecule binds to it. Molecular 
mechanics methods may also be used to provide semi-quantitative prediction of the binding 
affinity. Also, knowledge-based scoring function may be used to provide binding affinity 
estimates.  
Drug design with the help of computers may be used at any of the following stages of 
drug discovery, 
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1. Hit identification using virtual screening (structure- or ligand-based design) 
2. Hit-to-lead optimization of affinity and selectivity (structure-based design, QSAR, etc.) 
3. Lead optimization: optimization of other pharmacokinetic properties while maintaining 
affinity. 
In order to overcome the insufficient prediction of binding affinity calculated by recent scoring 
functions, the protein-ligand interaction and a compound’s 3D structure information are used for 
analysis. (43) 
Active site identification 
Active site identification is the first step in this program. It analyzes the protein to find 
the binding pocket, derives key interaction sites within the binding pocket, and then prepares the 
necessary data for Ligand fragment link. The basic inputs for this step are the 3D structure of the 
protein and a pre docked ligand in PDB format, as well as their atomic properties. Both ligand 
and protein atoms need to be classified and their atomic properties should be defined, basically, 
into four atomic types: 
1. Hydrophobic atom: All carbons in hydrocarbon chains or in aromatic groups. 
2. H bond donor: Oxygen and nitrogen atoms bonded to hydrogen atom(s). 
3. H bond acceptor: Oxygen and sp2 or sp hybridized nitrogen atoms with lone electron pair(s). 
4. Polar atom: Oxygen and nitrogen atoms that are neither H bond donor nor H bond acceptor, 
sulfur, phosphorus, halogen, metal, and carbon atoms bonded to heteroatom(s).(44) 
DOCKING 
Docking involves the fitting of a molecule into the target structure in a variety of 
positions, conformations and orientations. Molecular docking is used to predict the structure of 
intermolecular complex formed between two molecules. The small molecule called ligand 
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usually interacts with protein’s binding sites.(45)  Binding sites are areas of protein known to be 
active in forming of compounds. There are several possible mutual conformations in which 
binding may occur. These are commonly called binding modes. It also predicts the strength of 
the binding, the energy of the complex; the types of signal produced and calculate the binding 
affinity between two molecules using scoring functions.(46) 
TYPES OF DOCKING 
Lock and key or rigid docking- In lock and key docking, both the internal geometry of the 
receptor and ligand is kept fixed and docking was performed. 
Induced fit or flexible docking- An enumeration on the rotations of one of the molecules 
(usually smaller one) is performed. For every rotation the surface cell occupancy and energy is 
calculated; later the most optimum pose was selected. (45) 
ARGUS LAB 
Argus lab 4.0 distributed freely and is made available for windows platforms by Planaria 
Software. It is an introductory molecular modelling package for academics. The Argus docking 
engine approximates an exhaustive search method with similarities to AUTO DOCK and 
GLIDE. 
Flexible ligand docking possible with Argus lab where the ligand is described as torsion 
tree or free and grids are constructed that overlay the binding site.  The key features such as “the 
nature of binding site and the number of rotatable bonds to the ligand, can be determined. (46) 
STEPS INVOLVED IN DOCKING 
Docking is done by using ARGUS LAB Software. 
1. Protein preparation. 
2. Selection of active site (Q-Site finder). 
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3. Ligand Preparation. 
4. Docking Procedure. 
5. Visualization / Interpretation of Docking. 
1. PROTEIN PREPARATION 
Step: 1 
 Enter protein (pdb) ID in the protein data bank. (1TPY) 
 Go to download files and select pdb as text file. 
 Save the download pdb (text file) to the desktop. 
Step: 2 
 Open Argus lab file Open Import pdb file from the desktop. 
 3D Structure of the protein will appear in the workspace of Argus lab. 
 Left side of the screen shows molecular tree view. 
 Open pdb Open ‘residues’ ‘Open misc’ 
 From ‘Misc’ delete the inhibitor and hetero residues [Note: Do not delete  Co    
factor] 
 Open water press shift, select all water molecules and delete. 
 Add hydrogen atoms. 
 Go to Calculation on the toolbar energy by UFF method start. 
 Save the prepared protein as *.agi file format in the desktop. 
2. Q-SITE FINDER (47) 
Step: 1 
 Open Q-Site finder through online. 
 Upload / Import the PDB format of the Protein. 
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 Find all the active site and make a list out of the common amino acid residues. 
Step: 2 
 Open residues open Amino acids. 
 Press control and select the amino acids which were listed from the Q-Site   
finder. 
 Make sure that all amino acid residues listed are selected. 
 Right click on the mouse make a group from the selected residues give name 
Binding site Ok. 
3. LIGAND PREPARATION 
 Draw the structure from Chem sketch and save as MDL Mol format. 
 Import the ligand into workspace of Argus lab. 
 Clean Geometry Clean Hybridization. 
 Select the ligand, Right click on the mouse Make a group from the residues give name 
ligand Ok. 
4. DOCKING PROCEDURE 
 Select the set up a Dock Ligand calculation from the toolbar. 
 Argus Dock as the Docking Engine. 
 Dock was selected as calculation type. 
 Flexible for the scoring function. 
 Calculation size. 
 Start docking. 
 Save the Docked protein Ligand complex as Brookhaven pdb files (*.pdb). 
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5. VISUALIZATION / INTERPRETATION OF DOCKING 
 Molegro Molecular viewer will help in analyzing the energies and interaction of the 
binding. 
 View Docking view & Secondary Structure view. 
 View Hydrogen bond interaction. 
 Ligand map Interaction overlay. 
IN-SILICO SCREENING OF DRUG LIKENESS 
A drug to be pharmacologically active and exert the action it should possess 
Pharmacokinetic properties like absorption, distribution, metabolism and excretion. In the field 
of drug research and development many drug failures occur due to unfavorable ADME 
properties. This has to be ruled out earlier in the process of drug discovery. Some computational 
methods have been evolved to investigate the most suitable drug molecules before synthesis. (48) 
“Lipinski’s rule of five” it is also known as Pfizer’s rule of five is rule to evaluate drug 
likeness. It is used to predict whether a molecule is likely to be orally bio-available or to evaluate 
drug likeness. 
Lipinski’s rule 
Lipinski’s rule is used to predict if a molecule is likely to be orally bio-available or to 
evaluate drug likeness. The rule was formulated by Christopher A. Lipinski in 1997. The rule 
states that for drug likeness the molecule should have the following properties. 
  Molecular weight less than 500 Daltons. 
  Calculated log P value less than 5. 
  Less than 10 hydrogen bond acceptor groups(e.g.-O-,-N-,etc). 
  Less than 5 hydrogen bond donor groups (eg .NH ,OH etc). 
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  Less than 10 rotatable bonds. 
The designed and docked molecules are screened insilico using Molinspiration 
Cheminformatics software to evaluate drug likeness. This tool is quick and easy to use. It is a 
software available online for calculation of important molecular properties (log P, polar surface 
area, number of hydrogen bond donors and acceptors and others),as well as prediction of 
bioactivity score for the most important drug targets(GPCR ligands, kinase inhibitors, ion 
channel modulators, nuclear acceptors. (49) 
ADME ANALYSIS 
A deeper understanding of the relationships between important ADME parameters and 
molecular structure and properties has been used to develop in silico models that allow the early 
estimation of several ADME properties. Among other important issues, prediction of properties 
that provide information about dose size and dose frequency such as oral absortion, 
bioavailability, brain penetration clearance and volume of distribution (for frequency) also 
needed. (50) 
Absorption 
A compound crossing a membrane by purely passive diffusion, a reasonable permeability 
estimate can be made using single molecular properties, such as log D (diffusion co-efficient) or 
hydrogen- bonding capacity. The simplest Insilico models for estimating absorption are based on 
a single descriptor, Such as log P (partition coefficient) or log D, or polar surface area, which is a 
descriptor of hydrogen – bonding potential. Different multivariate approaches such as multiple 
liner regressions, partial least squares and artificial neural networks, have been used to develop 
quantitative structure-human-intestinal-absorption relationships. 
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Bioavailability 
Important properties for determining permeability seem to be the size of the molecule, as 
well as its capacity to make hydrogen bonds, its overall lipophilicity and possibly its shape and 
flexibility. 
Blood –Brain Barrier penetration (BBB) 
Drugs that act in the CNS need to cross the blood-brain barrier (BBB) to reach their 
molecular target by contrast, for drugs with a peripheral target, little or no BBB penetration 
might be required in order to avoid CNS side affections. Rule –of –five like recommendations 
regarding the molecular parameters that contribute to the ability of molecules to cross the BBB 
have been  made to aid BBB- penetration predictions; for example molecules with a molecular 
mass of <450Da or with polar surface area (PSA) <100A0 are more likely to penetrate the BBB. 
Dermal and ocular penetration 
The existing transdermal models are typically a function of the octanol/water partition 
coefficient and dermas that have been associated with aqueous solubility, including hydrogen – 
bonding parameters, molecular weight and molecular flexibility. Commercial models for the 
prediction of solute –permeation rates through the skin are available, for example qikrop and 
Derm Win programs. 
METABOLISM 
Insilico approaches to predicting metabolism can be divided into QSAR and three 
dimensional –QSAR studies, protein and pharmacophore models and predictive database. Some 
of the first –generation predictive –metabolism tools currently require considerable input from a 
computational chemist, whereas others can be used as rapid filters for the screening of virtual 
libraries. Perhaps the most intellectually satisfying molecular modeling studies are those based 
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on the crystal structure of the metabolizing enzymes. Ultimately, such programs might be linked 
to computer-aided toxicity prediction on the basis of quantitative structure-toxicity relationships 
and expert systems for toxicity evaluation. (51) 
TOXICITY PREDICTION 
All the data set molecules were subjected to the toxicity risk assessment by using Osiris 
program, which is available online. The OSIRIS property Explorer shown in this page is an 
integral part of Actelion's in house substance registration system. It allows drawing chemical 
structures and also calculates various drug relevant properties whenever a structure is valid. 
Prediction results are color coded in which the red color shows high risks with undesired effects 
like mutagenicity or a poor intestinal absorption and green color indicates drug-conform 
behavior. (52) 
Molecular property prediction includes 
 Toxicity risk assessment 
 clog P prediction 
 Solubility prediction 
 Molecular weight 
 Drug likeness prediction 
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SYNTHETIC METHODOLOGY 
SYNTHESIS 
Synthetic scheme was framed for the hit compounds from docking and the procedure for 
synthesis was collected from literatures. The necessary chemicals of laboratory grade for the 
synthesis where procured from Sigma Aldrich and Synthesis was carried out. 
Scheme 1( 53) 
2-Acetyl thiophene (0.01mol) and appropriately substituted N, N Dimethyl amino 
benzaldehyde (0.012 mol) were mixed in ethanol (20ml) containing 10% aq. Potassium 
hydroxide (8ml) and magnetically stirred the solution constantly at room temperature for 10 
hours. The whole mixture was transferred in to 100ml ice cold water and acidified with 
dil.Hydrochloric acid.The solid form was washed, filtered and dried, recrestallised from absolute 
ethanol. 
Compound 1
S O
CH3
N
CH3
CH3
O
S
O
N
CH3
CH3
+
Ethanolic KOH
Compound 2: 
2-Acetyl thiophene (0.01mol) and appropriately substituted O-Nitro benzaldehyde  
(0.012 mol) were mixed in ethanol (20ml)containing 10% aq.potassium hydroxide (8ml) and 
magnetically stirred the solution constantly at room temperature  for 10 hours . The whole 
mixture was transferred in to 100ml ice cold water and acified with dil.Hydrochloric acid.The 
solid form was washed, filtered and dried, recrestallised from absolute ethanol. 
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Compound 3: 
The compound was synthesized by two a step reaction. 
Step1: (53) 
2-Acetyl thiophene  (0.01mol) and appropriately substituted 2,4 Di Chloro benzaldehyde  
(0.012 mol) were mixed in ethanol (20ml)containing 10% aq. Potassium hydroxide (8ml) and 
magnetically stirred the solution constantly at room temperature  for 10 hours . The whole 
mixture was transferred in to 100ml ice cold water and acified with dil.Hydrochloric acid.The 
solid form was washed, filtered and dried , recrestallised from absolute ethanol . 
S
CH3
O Cl
Cl
O
S
Cl
ClO
+
Ethanolic KOH
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Step 2(54) 
A mixture of chalcone (0.02mol),thiosemicarbazide (0.02mol)were dissolved in ethanolic 
sodium hydroxide solution (10ml) was stirred for 3hrs.then it was poured into 400ml of cold water 
with continuous stirring for 1hour then left overnight. The precipitate formed was filtered, washed 
and recrystallised from ethanol.
 
S
N N
NH2
Cl
Cl
S
Cl
O
+
NH2
S
NH
NH2
NaOH\Ethanol
 
REACTANT PROFILE 
2 Acetyl thiophene 
S
CH3
O
 
Molecular formula                         :   C6H6OS 
Molecular weight                           :   126.18 
Appearance                                   :   Light yellowish liquid 
Melting point                                 :   10-11 
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N, N Dimethyl amino benzaldehyde 
N
CH3
CH3
OHC
 
Molecular formula  :       C9H11N0 
Molecular weight  :       149.19 
Appearance   :       Yellow white powder 
Melting point   :       74°c 
O-Nitro benzaldehyde 
OHC
O2N
 
 
 
Molecular formula  :             C7H5NO3 
Molecular weight  :             151.11 
Appearance   :              Pale yellow crystalline powder 
Melting point   :              41-44°c 
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2, 4 Di chloro benzaldehyde 
 
Cl
Cl
OHC
 
Molecular formula  :              C7H4Cl2O 
Molecular weight  :              175.01 
Appearance   :             White crystalline solid 
Melting point   :              64-69°C 
 
Thiosemicabazide 
NH2
S
NH
NH2
 
Molecular formula :         CH5N3S 
Molecular weight :         91.14 
Appearance  :        White crystalline solid 
Melting point  :        177-179°C 
 
RECRYSTALLISATION: 
Ethanol was added to the synthesised compounds and heated until it dissolved completely 
.The clear solution thus obtained was filtered immediately and set aside for cooling .On cooling 
crystals gradually appeared. 
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CHARACTERISATION STUDIES 
MELTING POINT 
          The melting point of the synthesized compound was determined by tone end open capillary 
tube method. The temperature at which the compound starts losing its crystallinity and changes from 
solid to liquid form was found recorded. 
IR SPECTROSCOPY 
        IR spectroscopy helps to ascertain the presence and absence of the functional group. The 
synthesized compound was made into a pellet with potassium bromide by pressed pellet technique 
using pellet press (Model No: M15). The pellet was mounted on the pellet disc and percentage 
transmittance was recorded in ABB IR Spectrophotometer (Model No: 3000). IR Spectroscopy is an 
important tool for structure elucidation and compound identification. 
EXAMPLE: 
  OH groups                : 3600-3200 cm-1 
  C=Ogroups             : 1710 cm-1 
  Ar C-H str               : 3050 -3000cm-1 
  C=C str                    : 1600 cm-1 
  N-S str                     : 3540-3300 cm-1 
  C-H aliphatic str      : 2795-2840 cm-1 
NMR SPECTROSCOPY 
           Proton NMR Spectroscopy helps us to study the number of equivalent protons and their 
environment thereby we can ascertain the structure of the molecule. The NMR spectra was recorded 
on 300 MHz BRUKER Advance III NMR Spectrometer DMSO was used as a solvent. 
MASS SPECTROSCOPY 
            Mass Spectra was recorded on Shimadzu HPLC-MS using Electron Spray Ionization 
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Technique and was quantified using Lab Solutions Software 7.0, Samples were prepared by 
dissolving a minute quantity of pure compounds in methanol. The fragmentation patterns were 
reported in m/z values. (55) 
HYPHENATED TECHNIQUE 
GC-MS: To determine the mass and also get an idea about the purity of the sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials And Methods 
 
Department of Pharmaceutical chemistry Page 48 
 
BIOLOGICAL EVALUATION 
ANTI-TB ACTIVITY 
             There are various high through put assays available for screening of new chemical 
entities against Tuberculosis. They are 
  Microplate Alamar blue Assay 
  BACTEC Assay 
  Luciferous reporter phage assay 
  REMA Assay 
  Broth Dilution Assay 
  Middle brook (7H9,7H10,7H11) Agar Dilution Assay 
PRINCIPLE 
             The micro plate Alamar blue assay (MABA) is an indirect colorimetric DST method for 
determining the MICs of TB drugs for strains of mycobacterium tuberculosis . in this assay , the 
redox indicator alamar blue monitors the reducing environment of the living cell . It turns from 
blue to pink in the presence of mycobacterial growth. 
PROCEDURE 
 The anti-mycobacterial activity of compounds (M13,M14) were assessed against 
M.tuberculosis using micro plate Alamar blue assay(MABA) 
 This methodology is non – toxic, uses a thermally stable reagent and shows good 
correlation with proportional and BACTEC radiometric method. 
 Briefly, 200ml of sterile de-ionised water was added to all outer perimeter wells of sterile 
96 wells plate to minimized evaporation of medium in the test wells during incubation. 
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 The 96 wells plate received 100 ml of the middle brooke 7H9 broth and serial dilution of 
compounds was made directly on a plate. 
 The final drug concentrations tested were 100 to 0.8mg/ml 
 Plates are covered and sealed with paraflim and incubated at 37c was dive days 
 After this time 25 ml of freshly prepared 1:1 mixture of alamar blue reagent and 10% 
tween 80was added to the plate and incubated for 24 hours. 
 A blue colour in the well was interpreted as no bacterial growth, and pink colour was 
scored as growth. 
 The MIC was defined as lowest drug concentration which prevented the colour change 
from blue to pink .(56) 
ADVANTAGES 
 It has accurate time-course measurement 
 It has highly sensitivity and linearity 
 It is ideal for use with post-measurement functional assays 
 It is flexible and it can be used with different cell modes  
 It is scable and it can be used with flourescence  and /or absorbance-based 
instrumentation platforms 
 It is non toxic , on –radioactive and is safe for the user, 
APPLICATIONS 
 Especially meant for studies on Mycobacterium tuberculosis  
 Used extensively in cell viability and cytotoxicity. 
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5. RESULTS AND DISCUSSION 
Nearly 200 molecules were sketched using chemsketch. Were docked against the enzyme 
using A. L 4.0.1 Software. The molecules were also docked against the following targets. The 
molecule with best docking score and interaction were selected and synthesis. 
The molecules were also docked against the following targets: 
1. Methoxy mycolic acid synthase 2 
2. Glutamine synthatese 1 
3. Cyclopropane mycolic acid synthase 2 
4. Decaprenylphosphoryl-b-d-ribose2’-Epimerase1 (DprE1) 
Table no: 1 
NAME OF THE 
ENZYME 
DOCKING SCORE ( K cal/ mol) 
DKS1 DKS2-1 DKS3 
Methoxy mycolic 
acid synthase 2 
 
-10.67 
 
-10.76 
 
-8.30 
Glutamine  
synthatase 1 
 
-10.53 
 
-9.45 
 
-8.43 
Cyclopropane 
Mycolic Acid 
synthase 2 
 
-9.56 
 
-10.72 
 
-9.0 
L.D Transpeptidase -9.78 -10.72 -7.2 
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INTERACTIONS OF THE DOCKED MOLECULE USING THE ENYME METHOXY 
MYCOLIC ACID SYNTHASE 2 
Table no: 2 
SAMPLE 
CODE 
 
DOCKING VIEW 
INTERACTION WITH 
AMINO ACIDS 
 
 
 
 
DKS1 
 
 
 
 
 
 
 
 
 
 
 
 
DKS2-1 
 
 
 
 
 
 
 
 
 
 
 
DKS3 
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RESULTS OF SCHEME 
COMPOUND NAME: DKS1 
 
IUPAC NAME: ( 2E)-3-[4-(dimethylamino)phenyl]-1-thien-2-ylprop-2-en-1-one 
Molecular formula                     :     C15H15NOS 
Molecular weight                       :     257.35g/mol 
Appearance                               :    Reddish orange 
Melting point                             :     69°c 
Composition                              :     C(70.01%)H(5.87%)N(5.44%)O(6.22%)S(12.46%) 
Molar refractivity                       :      79.80±0.3cm3 
Molar volume                            :     217.2±3.0cm3 
Surface tension                          :     49.4±3.0dyne/cm 
Density                                     :    1.184±0.06g/cm3 
Parachor                                   :    31.63±0.5,10-24cm3 
Index of refraction                     :      1.655±0.02 
Polarizability                             :     31.63±0.5,10-24cm3 
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COMPOUND NAME: DKS2-1 
 
IUPAC NAME                         :         5-(2,4-dichlorophenyl)-3-thien-2-yl-4,5-dihydro-1H-     
                                                                                pyrazole-1-carbothioamide 
Molecular formula                    :           C14H11CL2N3S2 
Molecular weight                      :           356.29 
Appearance                              :           yellowish brown 
Melting point                            :           72°c 
Composition                             :           C(47.19%)H(3.11%)C(19.90%)N(11.79%)S(18.00%) 
Molar refractivity                      :           92.68±0.5cm3 
Molar volume                           :           226.5±7.0cm3 
Surface tension                         :           58.8±7.0dyne/cm 
Density                                    :           1.57±0.1g/cm3  
Parachor                                  :           627.5±8.0cm3 
Index of refraction                    :           1.754±0.05 
Polarizability                            :           36.74±0.5,10-24cm3 
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COMPOUND NAME: DKS3 
 
IUPAC NAME                         :        (2E)-3-(2-nitrophenyl)-1-thien-2-ylprop-2-en-1-one 
Molecular formula                    :         C13H9NO3S 
Molecular weight                      :         259.38 
Appearance                              :         Light brown 
Melting point                            :        67°c 
Composition                             :       C(60.22%)H(3.50%)N(5.40%)O(18.51%)S(12.37%) 
Molar refractivity                      :      72.03±0.3cm3 
Molar volume                           :      191.1±3.0cm3 
Surface tension                         :      58.9±3.0dyne/cm3 
Density                                    :      1.346±0.06g/cm3 
Parachor                                  :      529.6±4.0cm3 
Index of refraction                    :      1.677±0.02 
Polarizability                            :     28.55±0.5,10-24cm3 
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IR SPECTROSCOPY 
The sample were prepared by the KBr pellet techniques of spectrum. The spectra were 
examined for the absence of the functional groups of the parent compounds and examined for the 
presence of the vibrational absorption band for the new functional group. 
The synthetic reaction involves, two compounds invoved in  the reaction between ketone 
and aldehydes  to yield chalcones  . Another one compound invoved in the reaction between 
chalcones and thiosemicarbazide to yield benzimidazole derivative. 
Table no :3 
ABSORBANT BAND 
 
DKS1 DKS2-1 DKS3 
C=0 Stretching       
Ar C-H Stretching ×   
 
× 
 
C=C Stretching     
 
  
 
 
N=N Stretching 
 
×   × 
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SAMPLE CODE : DKS1 
 
SAMPLE CODE : DKS2-1 
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SAMPLE CODE : DKS3 
 
 
 
 
 
 
 
 
 
 
Results and discussion 
 
Department of Pharmaceutical chemistry Page 58 
 
NMR SPECTROSCOPY 
SAMPLE CODE :DKS1 
 
Table no. 4 
S.NO § VALUE NATURE OF PEAK 
NUMBER OF 
PROTONS 
1 6.62 Doublet 2 protons 
2 6.70 Doublet 2 protons 
3 7.24-7.25 Multiplet 3 protons 
4 7.42 Singlet 1proton 
5 7.45 Singlet 2protons 
6 7.60 Doublet 2 protons 
7 7.75 Singlet 2protons 
8 8.04-8.05 Doublet 1proton 
 
Results and discussion 
 
Department of Pharmaceutical chemistry Page 59 
 
 
SAMPLE CODE : DKS2-1 
 
Table no: 5 
 
S.NO 
 
§ VALUE 
 
NATURE OF PEAK 
 
NUMBER OF 
PROTONS 
1 7.84 ppm Triplet 1proton 
2 7.85ppm Singlet 1proton 
3 7.90-7.97ppm Multiplet 1proton 
4 7.33-7.23 Multiplet 3protons 
5 7.17-7.22 Multiplet 3protons 
6 1.166-1.22 Multiplet 1proton 
7 o.871-0.937 Multiplet 1proton 
Results and discussion 
 
Department of Pharmaceutical chemistry Page 60 
 
SAMPLE CODE : DKS3 
 
Table no: 6 
S.NO § VALUE (PPM) NATURE OF PEAK 
NUMBER OF 
PROTONS 
1 8.05ppm Doublet 1 proton 
2 7.55-7.78ppm Multiplet 1proton 
3 7.80-7.84ppm Multiplet 2proton 
4 7.87 ppm Doublet 1proton 
5 7.95ppm Doublet 1proton 
6 7.36ppm Doublet 2proton 
7 1.34ppm Triplet 1proton 
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GC-MS SPECTROSCOPY 
The molecular weight of the synthesised compounds were comfirmed by GC-MASS 
analysis 
Table no:7 
SAMPLE CODE CALCULATED MASS 
ACTUAL MASS 
 
DKS1 257.35g/mol 
257.0 g/mol 
 
DKS2-1 352.29g/mol 
352.20g/mol 
 
DKS3 259.38g/mol 
 
259.27g/mol 
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SAMPLE CODE : DKS1 
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SAMPLE CODE :DKS2-1 
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SAMPLE CODE : DKS3 
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IN-SILICO TOXICITY  PREDICTION 
All the data set molecules were subjected to the toxicity risk assessment by using Osiris 
program, which is available online. The OSIRIS property Explorer shown in this page is an integral 
part of Actelion's in house substance registration system. It allows drawing chemical structures and 
also calculates various drug relevant properties whenever a structure is valid. Prediction results are 
color coded in which the red color shows high risks with undesired effects like mutagenicity or a 
poor intestinal absorption and green color indicates drug-conform behavior. 
Table no: 8 
SAMPLE DKS1 DKS2-1 DKS3 
MUTAGENIC - + + 
TUMORIGENIC - + + 
IRRITANT + + + 
REPRODUCTIVE EFFECTIVE + - + 
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SAMPLE CODE : DKS1 
 
 
SAMPLE CODE : DKS2-1 
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SAMPLE CODE :DKS3 
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BIOLOGICAL EVALUATION 
The final pure compounds were screened for Anti-mycrobial activity by in vitro method 
called Microplate Alamar Blue Assay (MABA) 
Table no: 9 
S.N
O 
SAMP
LE 
CODE 
100µg/
ml 
50µg/
ml 
25µg/
ml 
12.5µg/
ml 
6.25µg/
ml 
3.12µg/
ml 
1.6µg/
ml 
0.8µg/
ml 
50µg/
ml 
1 
DK 
S1 S S R R R R R R R 
2 
DKS 
2-1 S S R R R R R R R 
3 
DK 
S3 S S R R R R R R 
R 
 
NOTE: 
S- Sensitive 
R-Resistant 
Strain used:M.Tuberculosis(H37RV strain) 
Here are the standard values for the anti –TB test which was performed. 
Pyrazinamide-3.125µg/ml 
Streptomycin-6.25µg/ml 
Ciprofloxazin-3.125µg/ml 
NOTE: 
S- Sensitive 
R-Resistant 
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Strain used:M.Tuberculosis(H37RV strain) 
Here are the standard values for the anti –TB test which was performed. 
Pyrazinamide-3.125µg/ml 
Streptomycin-6.25µg/ml 
Ciprofloxazin-3.125µg/ml 
Table no: 10 
SAMPLE DRUG PHOTOGRAPH 
S.NO SAMPLE 
CODE 
100µg/
ml 
50µg/
ml 
25µg/
ml 
12.5µ
g/ml 
6.25µg/
ml 
3.12µg/
ml 
1.6µg/m
l 
0.8µg
/ml 
50µg/
ml 
1 DKS1 
 
2 DKS2-1 
3 DKS3 
 
Table no: 11 
STANDARED DRUG PHOTOGRAPH 
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DISCUSSION 
Finally all the reports were discussed, that the purity of the compounds are confirmed by 
sharp melting point and TLC. Then the molecular weights of the compounds are confirmed by 
NMR and the functional groups of the formed structure were confirmed by absorption bands 
obtained in the spectra. Among 3 compounds, one compound was 100%  pure in nature it was 
concluded by GC-MS. 
Toxicity of the compounds are reported, that 2 compounds are non-toxic and one 
compound was slightly toxic in nature. 
The biological activity of the compounds are evaluated by MABA and the final results 
concluded, that all the 3 compounds are not match with standard drugs. The activity of the 
compounds sensitive only at 50µg/ml.  
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6.SUMMARY AND CONCLUSION 
 Methoxy mycolic acid synthase 2 (1TPY) a critical enzyme for the growth of 
Mycobacterium tuberculosis was chosen for our study after review of literature. 
 A database of 200 scaffolds with high prospect of inhibiting the target 1TPY were 
carefully chosen by making changes to the known hit molecules , here the chalcones 
and thiophene  nucleus. 
 Candidate molecules were designed and docked against 1TPY protein using Argus 
lab 4.1 software. 
 Three molecules with good Docking score (lower binding energy) and interactions 
were shortlisted for synthesis. The reaction conditions were optimized. 
 The selected molecules were subjected to Toxicity Prediction assessment by OSIRIS 
software. The results are color Coded as green color which confirms the drug likeness  
 The molecules were labeled as DKS1, DKS2-1,DKS3 and synthesized with 
satisfactory yield. 
 Purity of the synthesized compounds was ensured by repeated  recrystallization .The                    
compounds were evaluated by TLC. and Melting point determination. 
 The characterization of the synthesized compounds was done using Infra-red, Nuclear 
Magnetic Resonance and Mass spectroscopic methods. 
 The final pure compounds were screened for Anti- mycobacterial activity by in vitro 
method called Microplate Alamar Blue Assay (MABA). 
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CONCLUSION 
 Our work concludes that our synthesized molecules are effective in inhibiting enzyme 
Methoxy mycolic acid synthase 2 (1TPY) which is important for the growth of 
             Mycobacterium tuberculosis. 
 All the three compounds gave Docking score between -7.00 to -10 kcal/mol. 
Pyrazinamide gave Docking score of -5.6 for 1TPY, Streptomycin gave Docking 
score of -7.4 for 1TPY and Ciprofloxacin gave Docking score of -5.9 for 1TPY. 
There is correlation between the core and activities of all the three compounds which 
were tested and compared with the standard drugs. This goes to prove that Methoxy 
Mycolic Acid Synthase2 (1TPY) is a critical enzyme for anti-mycobacterial activity. 
 The minimum inhibitory concentration of 3 of the synthesized compounds ranged 
from 50μg/ml which is compared to that of the known anti-TB agents. 
Pyrazinamide - 3.125μg/ml, 
Ciprofloxacin - 3.125μg/ml and 
Streptomycin - 6.25μg/ml. 
 A further refinement to the structure of the synthesized compounds is expected to 
yield new outlook to the development of promising molecules against the pathogen      
Mycobacterium tuberculosis. 
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